1. Home
  2. HEI vs ALNY Comparison

HEI vs ALNY Comparison

Compare HEI & ALNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • HEI
  • ALNY
  • Stock Information
  • Founded
  • HEI 1957
  • ALNY 2002
  • Country
  • HEI United States
  • ALNY United States
  • Employees
  • HEI N/A
  • ALNY N/A
  • Industry
  • HEI Aerospace
  • ALNY Biotechnology: Pharmaceutical Preparations
  • Sector
  • HEI Industrials
  • ALNY Health Care
  • Exchange
  • HEI Nasdaq
  • ALNY Nasdaq
  • Market Cap
  • HEI 33.2B
  • ALNY 33.2B
  • IPO Year
  • HEI N/A
  • ALNY 2004
  • Fundamental
  • Price
  • HEI $240.00
  • ALNY $264.99
  • Analyst Decision
  • HEI Buy
  • ALNY Buy
  • Analyst Count
  • HEI 11
  • ALNY 24
  • Target Price
  • HEI $270.20
  • ALNY $299.09
  • AVG Volume (30 Days)
  • HEI 605.0K
  • ALNY 643.5K
  • Earning Date
  • HEI 02-24-2025
  • ALNY 02-13-2025
  • Dividend Yield
  • HEI 0.09%
  • ALNY N/A
  • EPS Growth
  • HEI 26.12
  • ALNY N/A
  • EPS
  • HEI 3.67
  • ALNY N/A
  • Revenue
  • HEI $3,857,669,000.00
  • ALNY $2,094,795,000.00
  • Revenue This Year
  • HEI $10.69
  • ALNY $24.87
  • Revenue Next Year
  • HEI $7.28
  • ALNY $18.53
  • P/E Ratio
  • HEI $65.67
  • ALNY N/A
  • Revenue Growth
  • HEI 29.97
  • ALNY 21.54
  • 52 Week Low
  • HEI $178.20
  • ALNY $141.98
  • 52 Week High
  • HEI $283.60
  • ALNY $304.39
  • Technical
  • Relative Strength Index (RSI)
  • HEI 49.81
  • ALNY 61.89
  • Support Level
  • HEI $222.18
  • ALNY $245.69
  • Resistance Level
  • HEI $231.92
  • ALNY $256.93
  • Average True Range (ATR)
  • HEI 5.33
  • ALNY 9.38
  • MACD
  • HEI 1.70
  • ALNY 2.95
  • Stochastic Oscillator
  • HEI 88.46
  • ALNY 99.91

About HEI Heico Corporation

Heico is an aerospace and defense supplier that focuses on creating niche replacement parts for commercial aircraft and components for defense products. In commercial aerospace, Heico is the largest independent producer of replacement aircraft parts. In the defense market, the company produces niche subcomponents used in targeting technology as well as simulation equipment, among other categories. It operates as two segments: the flight support group,or FSG, and the electronic technologies group, or ETG, both of which supply the aerospace and defense sectors to different degrees. The company is persistently acquisitive, focusing on companies in similar or adjacent markets that are generating strong cash flow and profitable growth potential.

About ALNY Alnylam Pharmaceuticals Inc.

Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.

Share on Social Networks: